AUTOANTIBODIES AGAINST HUMAN BETA-DEFENSIN-2 IN THE BLOOD SERUM OF PATIENTS WITH VULVAL AND CERVICAL CANCER

Shnitsar V.M., Soldatkina M.A.¹, Zinchenko I.I.², Markeeva N.V.³, Rodnin N.V.⁴, Nespryadko S.V.⁵, Turchak O.V.⁶, Vinnitskaya A.B.⁶, Pogrebnoy P.V.¹

• ¹R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine
• ²R.E. Kavetsky Institute of Experimenthal Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
• ³
• ⁴Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv, Ukraine
• ⁵National Cancer Institute, Kyiv, 03022, Ukraine
• ⁶Institute of Oncology, AMS of Ukraine, Kyiv, Ukraine

Summary. The relevant levels of autoantibodies against hBD-2 in the blood serum of healthy donors, 13 patients with vulval cancer and 4 patients with cervical cancer have been studied by ELISA using recombinant hBD-2 as an antigen. In the serum of patients with vulval cancer of stages III–IV, the elevated levels of the anti-hBD-2-autoantibodies are revealed.